Diabetes

Seattle, WA

91 Diabetes Trials near Seattle, WA

Power is an online platform that helps thousands of Diabetes patients discover FDA-reviewed trials every day. Every trial we feature meets safety and ethical standards, giving patients an easy way to discover promising new treatments in the research stage.

Learn More About Power
No Placebo
Highly Paid
Stay on Current Meds
Pivotal Trials (Near Approval)
Breakthrough Medication

Teplizumab for Type 1 Diabetes

Seattle, Washington
This is a multicenter, randomized, double-blind, parallel, placebo-controlled Phase 3, 2-arm study for treatment. The purpose of this study is to measure change in glycemic control and prandial insulin independency over 52 weeks with teplizumab compared with placebo, both administered by intravenous (IV) infusion, in participants with recently diagnosed Stage 3 type 1 diabetes (T1D) aged 1 to 25 years, on standard insulin therapy.
Pivotal Trial (Near Approval)

Trial Details

Trial Status:Recruiting
Trial Phase:Phase 3
Age:1 - 25

723 Participants Needed

Maridebart Cafraglutide for Obesity

Seattle, Washington
The primary objective of this study is to demonstrate that maridebart cafraglutide is superior to placebo for percent change in body weight.
Pivotal Trial (Near Approval)

Trial Details

Trial Status:Active Not Recruiting
Trial Phase:Phase 3

1105 Participants Needed

Tirzepatide vs Dulaglutide for Type 2 Diabetes

Seattle, Washington
The purpose of the trial is to assess the efficacy and safety of tirzepatide to dulaglutide in participants with type 2 diabetes and increased cardiovascular risk.
No Placebo Group
Pivotal Trial (Near Approval)

Trial Details

Trial Status:Active Not Recruiting
Trial Phase:Phase 3
Age:40+

13299 Participants Needed

Siplizumab for Type 1 Diabetes

Seattle, Washington
This is a multicenter, Phase Ib, open-label, siplizumab dose-finding study in individuals aged 8-45 years with a Type 1 diabetes mellitus (T1DM) diagnosis. within 18 months of V0. Participants will be randomized 1:1:1:1 to one of four possible siplizumab dosing arms. All dosing arms will receive weekly siplizumab doses for a total of 12 weeks. After the completion of treatment, participants will undergo follow-up visits at weeks 12, 24, 36 and 52 which include longitudinal MMTTs. If indicated, participants will enter into long-term safety monitoring for up to an additional 48 weeks. Blood samples for mechanistic analyses will be obtained during the treatment phase and thereafter. Adults aged 18- 45 will be enrolled initially at the study sites. The primary objective is to identify a safe, metabolically favorable, dosing regimen for siplizumab in patients with type 1 diabetes that induces changes in T cell phenotypes observed with alefacept therapy in new-onset T1DM. The secondary objectives are to: 1. Assess the safety profile of siplizumab in recently diagnosed T1DM. 2. Assess the effects of siplizumab on residual beta cell function in recently diagnosed T1DM participants.
No Placebo Group

Trial Details

Trial Status:Active Not Recruiting
Trial Phase:Phase 1, 2
Age:8 - 45

120 Participants Needed

Low-Dose ATG for Type 1 Diabetes

Seattle, Washington
A multi-center, placebo-controlled, double blind, 2:1 randomized control clinical trial testing low-dose ATG vs. placebo in subjects with a 2 year 50% risk of progression to stage 3 T1D.

Trial Details

Trial Status:Active Not Recruiting
Trial Phase:Phase 2
Age:6 - 34

101 Participants Needed

Rituximab + Abatacept for Type 1 Diabetes

Seattle, Washington
This trial is testing whether a combination of two drugs, rituximab-pvvr followed by abatacept, can better preserve insulin production in people newly diagnosed with Type 1 Diabetes compared to rituximab-pvvr alone. Rituximab-pvvr works by reducing harmful immune cells, while abatacept helps calm the immune system. The goal is to see if this combination can improve insulin production and overall diabetes management.
Prior Safety Data

Trial Details

Trial Status:Active Not Recruiting
Trial Phase:Phase 2
Age:8 - 45

74 Participants Needed

Frexalimab + Insulin for Type 1 Diabetes

Seattle, Washington
This trial is testing a new drug called frexalimab in young people with newly diagnosed Type 1 Diabetes. The goal is to see if it can help their bodies keep making insulin. The study will compare different doses of the drug to find the safest and most effective amount.

Trial Details

Trial Status:Recruiting
Trial Phase:Phase 2
Age:12 - 35

192 Participants Needed

Inspiratory Muscle Strength Training for Type 2 Diabetes

Seattle, Washington
High-resistance, short-duration inspiratory muscle strength training (IMST) is a novel lifestyle intervention involving 30 inhalations against a resistive load which requires only \~5 min/day and is thus ideal for youth with T2D (Y-T2D). Investigators seek to 1: assess changes in casual and 24-hr SBP, endothelial function, and arterial stiffness after 3 months of IMST vs. sham training in Y-T2D, 2: Define changes in eGFR andalbuminuria after 3 months of IMST vs. sham in Y-T2D, 3: Interrogate mechanisms of IMST by translational assessments of NO bioavailability, endothelial NO synthase (eNOS) activation, and ROS/oxidative stress, and determine the role of circulating factors.

Trial Details

Trial Status:Recruiting
Trial Phase:Unphased
Age:14 - 40

90 Participants Needed

Custom 3D Printed Insoles for Diabetes Foot Health

Seattle, Washington
In this research study, the investigators are evaluating if novel custom foot orthotics improves foot health and mobility for people who are at increased risk of developing foot ulcers. The investigators are comparing different methods of custom foot orthotic fabrication in people who are at increased risk of developing foot ulcers and individuals who are not. Participating in this study involves coming to the VA Hospital in Seattle for up to 12 study visits, lasting up to four hours. If eligible and choose to participate, participants will: * Wear custom foot orthotics during in laboratory testing for up to four hours * Receive a foot health assessment * Walk through the laboratory space so the investigators can see how the orthotics affect the participant's body movement * Participants will be paid for participating in the study
No Placebo Group

Trial Details

Trial Status:Active Not Recruiting
Trial Phase:Unphased

25 Participants Needed

CNP-103 for Type 1 Diabetes

Seattle, Washington
This study is a Phase 1b/2a First-in-Human (FIH) clinical trial to assess the safety, tolerability, pharmacodynamics (PD), and efficacy of multiple ascending doses of CNP-103. The approximately 208-day study consists of a Screening Period (28 days), Treatment Period (90 days), and Post-Dose Evaluations (90 days).

Trial Details

Trial Status:Recruiting
Trial Phase:Phase 1, 2
Age:12 - 35

72 Participants Needed

MiniMed NMX8-AID System for Diabetes

Seattle, Washington
The purpose of this study is to check that a new insulin pump, called NMX8, is safe when used with a continuous glucose monitoring sensor called Disposable Sensor 5 in people with diabetes. The study will include people with Type 1 diabetes who are 7-85 years old and people with Type 2 diabetes who are 18-85 years old. Patients will use their current therapy while also wearing the DS5 for up to 40 days. During this time, they will complete a meal and exercise log. Patients will then be put into one of three groups by a computer by chance and given the NMX8 pump to use for 90 days. During this time, patients will either bolus or not bolus for meals and continue to complete a meal and exercise log depending on the group they are in. Once their part in the study is over, if patients like the pump and want to keep using it, they may be able to join a Continued Access Period to keep using the NMX8 pump.
No Placebo Group

Trial Details

Trial Status:Not Yet Recruiting
Trial Phase:Unphased
Age:7 - 85

400 Participants Needed

Semaglutide for Type 1 Diabetes

Seattle, Washington
This trial is testing semaglutide, a drug that helps with heart, kidney, and blood sugar health, in adults with type 1 diabetes. The drug has shown benefits for people with type 2 diabetes, but it is not yet approved for type 1 diabetes. Researchers want to see if it can provide similar health improvements for this new group. Semaglutide has been evaluated in numerous trials for its effectiveness in improving blood sugar levels and weight loss in type 2 diabetes.
Pivotal Trial (Near Approval)

Trial Details

Trial Status:Recruiting
Trial Phase:Phase 3
Age:18 - 49

60 Participants Needed

Inhaled Insulin for Diabetes in Children

Seattle, Washington
This trial tests an inhalable insulin called Afrezza, combined with a long-acting insulin, in children and teenagers with diabetes. Afrezza helps lower blood sugar quickly after eating, and the long-acting insulin keeps it stable all day. The study aims to see if this combination is safe and effective.
No Placebo Group
Pivotal Trial (Near Approval)

Trial Details

Trial Status:Active Not Recruiting
Trial Phase:Phase 3
Age:4 - 17

319 Participants Needed

Cadisegliatin for Type 1 Diabetes

Seattle, Washington
This is a Phase 3 trial of cadisegliatin as adjunctive therapy to insulin in participants with Type 1 Diabetes Mellitus.
Stay on current meds
Pivotal Trial (Near Approval)

Trial Details

Trial Status:Recruiting
Trial Phase:Phase 3

150 Participants Needed

Dulaglutide for Type 2 Diabetes

Seattle, Washington
The main purpose of this study is to evaluate additional dosing options for dulaglutide in pediatric participants with Type 2 Diabetes. Participation in this study will last about 8 months.
No Placebo Group
Pivotal Trial (Near Approval)

Trial Details

Trial Status:Recruiting
Trial Phase:Phase 3
Age:10 - 17

55 Participants Needed

Semaglutide for Type 2 Diabetes

Seattle, Washington
A human subjects research study, the primary purpose of which is to assess the EFFECTS OF SEMAGLUTIDE ON INTRACRANIAL BLOOD FLOW AND BLOOD-BRAIN BARRIER PERMEABILITY IN TYPE-2 DIABETES (T2D) through testing of the intervention on patients in a clinical setting. The study will randomize subjects with diabetes to either semaglutide or matching placebo. Magnetic resonance images will be primary endpoint measured at baseline and at one year to assess effect of this FDA approved medication. Given the available evidence supporting the neuroprotective effect of this drug class and stroke reduction with semaglutide, and the investigators preliminary data showing that T2D had significantly reduced total number of distal arterial branches in the brain than non-T2D, the investigators expect treatment with semaglutide will be associated with improved intracranial blood flow condition.

Trial Details

Trial Status:Recruiting
Trial Phase:Phase 4
Age:40 - 65

50 Participants Needed

Adalimumab + Verapamil for Type 1 Diabetes

Seattle, Washington
This multi-center randomized controlled trial will assess the safety and efficacy of ATG followed by either adalimumab or verapamil in preserving insulin secretion 2 years from randomization in persons aged 9 to \<21 with recent-onset stage 3 T1D.

Trial Details

Trial Status:Not Yet Recruiting
Trial Phase:Phase 1, 2
Age:9 - 21

120 Participants Needed

Semaglutide for Diabetic Kidney Disease in Type 1 Diabetes

Seattle, Washington
The primary objective of this study is to determine the effects of semaglutide on kidney oxygenation and function in type 1 diabetes. The secondary objective is to determine the glycemic effects and safety of semaglutide in type 1 diabetes.

Trial Details

Trial Status:Recruiting
Trial Phase:Phase 2

60 Participants Needed

JAK Inhibitors for Type 1 Diabetes

Seattle, Washington
This trial is testing two medications, abrocitinib and ritlecitinib, which aim to reduce immune system activity. The study focuses on people who have been recently diagnosed with Stage 3 Type 1 Diabetes. These medications work by calming the immune system to prevent it from attacking insulin-producing cells in the pancreas.

Trial Details

Trial Status:Active Not Recruiting
Trial Phase:Phase 2
Age:12 - 35

78 Participants Needed

AZD5004 for Type 2 Diabetes

Seattle, Washington
This is a Phase IIb, randomised, double-blind, parallel-group, placebo-controlled study to evaluate the efficacy, safety and tolerability of AZD5004 in adults with type 2 diabetes mellitus, compared to placebo and active comparator.

Trial Details

Trial Status:Active Not Recruiting
Trial Phase:Phase 2

406 Participants Needed

Why Other Patients Applied

"I have already lost part of a leg to an infection. I want to try to get this horrific condition under control and get back to my life. It's taken enough."

WY
Diabetes PatientAge: 40

"Years ago, Metformin didn't help. I'm currently on Rybelsus & Farxiga. Not doing me much good. My insurance won't cover any of the injectables. Excited to try something new."

QL
Diabetes PatientAge: 71

"I've been in pain for years. It's been crippling and has massively impacted my life. I want to be free. Diabetes changed everything at 15. Diabetic Type 1 for 20 years. SEVERE Peripheral Neuropathy onset 7-8 years in. Have been living with it since. Have tried every drug, everything. Gaba, lyrica, all opioids, electrical current therapy, massages, acupuncture, cupping, everything. Currently taking low dose of duloxetine, have an insulin pump but its not good enough. Want to try a cutting-edge med."

YN
Diabetes PatientAge: 35

"I have had type 2 diabetes for some time now and would love to be part of a study... should the study drug work out as a successful treatment, then I would be glad to be one of the first patients in line!"

MB
Diabetes PatientAge: 67

"Looking for better ways to manage my diabetes, high blood pressure and overall health. Hoping to improve my health all together in order to have a better life & to enjoy my children & grandchildren."

OK
Diabetes PatientAge: 66

Inhaled Insulin for Type 1 Diabetes

Seattle, Washington
This investigator-initiated study will enroll about 30 adults 18 to 65 years of age with type 1 diabetes (T1D) who are using the Tandem t:slim X2 insulin pump or Tandem Mobi insulin pump with Control-IQ or Control-IQ+ technology ("Control-IQ" which will refer to either Control-IQ or Control-IQ+). The study is being done to find out if inhaled insulin given for a meal is safer and better to use than a bolus of insulin through your pump when you exercise following a meal. Participants are asked to complete three study exercise visits in the clinic.
No Placebo Group

Trial Details

Trial Status:Recruiting
Trial Phase:Unphased
Age:18 - 65

30 Participants Needed

Financial Incentives for Type 1 Diabetes

Seattle, Washington
The goal of this clinical trial is to see if a financial incentives program called InvesT1D is helpful to support diabetes management in adolescents with type 1 diabetes. Adolescent participants will be randomized to usual care or receive financial incentives for meeting diabetes self-management and clinical outcomes goals during the study. Researchers will compare changes in glucose levels, as well as adolescent and caregiver person-reported outcomes between groups.
No Placebo Group

Trial Details

Trial Status:Recruiting
Trial Phase:Unphased
Age:12 - 18

96 Participants Needed

Hybrid Closed Loop System for Type 1 Diabetes

Seattle, Washington
The purpose of this study is to evaluate the safety and effectiveness of the Hybrid Closed Loop system (HCL) in adult and pediatric patients with type 1 diabetes in the home setting. A diverse population of patients with type 1 diabetes will be studied. The study population will have a large range for duration of diabetes and glycemic control, as measured by glycosylated hemoglobin (A1C). They will be enrolled in the study regardless of their prior diabetes regimen, including using Multiple Daily Injections (MDI), Continuous Subcutaneous Insulin Infusion (CSII) or Sensor-Augmented Pump therapy (SAP)
No Placebo Group

Trial Details

Trial Status:Active Not Recruiting
Trial Phase:Unphased
Age:2 - 80

280 Participants Needed

Social Media Intervention for Type 1 Diabetes

Seattle, Washington
The goal of this clinical trial is to evaluate the feasibility of a social media intervention to support diabetes management in adolescents with type 1 diabetes. Adolescent participants will be randomized to receive diabetes education and peer support over Instagram or to usual outpatient diabetes care. Researchers will assess whether the social media intervention is feasible. In addition, the study team will also explore and compare changes in glucose levels and person-reported outcomes between the two groups.
No Placebo Group

Trial Details

Trial Status:Recruiting
Age:13 - 18

60 Participants Needed

Artificial Pancreas Systems for Type 1 Diabetes

Seattle, Washington
An artificial pancreas (AP) is a control system for automatic insulin delivery. The investigators have implemented a missed meal bolus detection algorithm for use within an AP control system. If a meal is detected that was not reported by the user, the system shall calculate the amount of meal insulin that will be dosed and deliver that insulin. The investigators will test how well the new algorithm manages glucose compared to the participant's usual care including the tslim X2 pump with Control IQ enabled. This type of algorithm may improve glucose control for high risk patient populations.
No Placebo Group

Trial Details

Trial Status:Recruiting

30 Participants Needed

Omnipod 5 System for Type 1 Diabetes

Seattle, Washington
Subject will undergo a 14-day outpatient, standard therapy phase during which sensor and insulin data will be collected. This will be followed by a 90-day outpatient phase where subjects will either use the Omnipod 5 system or continue to use their personal insulin pump with the study provided continuous glucose monitoring system.
No Placebo Group

Trial Details

Trial Status:Active Not Recruiting

200 Participants Needed

DMR for Type 2 Diabetes

Seattle, Washington
The Revita® system is being investigated to assess the efficacy of DMR versus Sham on improvement in Glycemic, Hepatic and Cardiovascular endpoints for patients with Type 2 Diabetes who are inadequately controlled on one or more glucose lowering agents. The purpose of this study is to demonstrate the efficacy and safety of the Fractyl DMR Procedure using the Revita® System compared to a sham. Subjects randomized to the DMR procedure will be followed per protocol till 48 weeks post treatment. Subjects in the Sham treatment arm will be offered cross over to receive the DMR treatment at 48 weeks and will be followed per protocol for 48 weeks post treatment.

Trial Details

Trial Status:Recruiting
Age:21 - 70

320 Participants Needed

Lower Radiotherapy Dose for Brain Tumors

Seattle, Washington
This phase II trial studies how well lower dose radiotherapy after chemotherapy (Carboplatin \& Etoposide) works in treating children with central nervous system (CNS) germinomas. Radiation therapy uses high energy x-rays, particles, or radioactive seeds to kill cancer cells and shrink tumors. Carboplatin is in a class of medications known as platinum-containing compounds. It works in a way similar to the anticancer drug cisplatin, but may be better tolerated than cisplatin. Carboplatin works by killing, stopping or slowing the growth of tumor cells. Etoposide is in a class of medications known as podophyllotoxin derivatives. It blocks a certain enzyme needed for cell division and DNA repair and may kill cancer cells. Researchers want to see if lowering the dose of standard radiotherapy (RT) after chemotherapy can help get rid of CNS germinomas with fewer long-term side effects.
No Placebo Group

Trial Details

Trial Status:Recruiting
Trial Phase:Phase 2
Age:3 - 29

240 Participants Needed

Insulin Dosing Calculator for Type 2 Diabetes

Seattle, Washington
The goal of this feasibility trial is to test whether a novel insulin dosing calculator can improve blood glucose management for patients with type 2 diabetes mellitus on hospital admission. The main questions it aims to answer are: * Whether using this calculator leads to no excessive hypoglycemia? * Whether using this calculator leads to a decrease of hyperglycemia? Participants will receive initial insulin doses by the calculator on hospital admission, and the rest of care will follow standard of care. Participants will be compared with patients in the UW observational cohort who received initial insulin doses by standard of care.
No Placebo Group

Trial Details

Trial Status:Recruiting

85 Participants Needed

Lanifibranor for Nonalcoholic Steatohepatitis (NASH)

Seattle, Washington
This Phase 3 study is conducted to evaluate lanifibranor in adults with NASH and liver fibrosis histological stage F2 or F3
Pivotal Trial (Near Approval)

Trial Details

Trial Status:Recruiting
Trial Phase:Phase 3

1000 Participants Needed

1234

Know someone looking for new options? Spread the word

Match to a Trial